GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Cyclically Adjusted PS Ratio

Arbutus Biopharma (STU:I9DN) Cyclically Adjusted PS Ratio : 13.02 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Arbutus Biopharma's current share price is €2.994. Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.23. Arbutus Biopharma's Cyclically Adjusted PS Ratio for today is 13.02.

The historical rank and industry rank for Arbutus Biopharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:I9DN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.02   Med: 5.22   Max: 16.21
Current: 13.29

During the past years, Arbutus Biopharma's highest Cyclically Adjusted PS Ratio was 16.21. The lowest was 1.02. And the median was 5.22.

STU:I9DN's Cyclically Adjusted PS Ratio is ranked worse than
75.69% of 506 companies
in the Biotechnology industry
Industry Median: 5.565 vs STU:I9DN: 13.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arbutus Biopharma's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.008. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.23 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted PS Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 6.06 8.72 6.21 9.22

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.28 6.63 6.22 9.22 10.43

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PS Ratio falls into.



Arbutus Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Arbutus Biopharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.994/0.23
=13.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.008/131.7762*131.7762
=0.008

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.060 100.560 0.079
201409 0.153 100.428 0.201
201412 0.158 99.070 0.210
201503 0.143 99.621 0.189
201506 0.056 100.684 0.073
201509 0.071 100.392 0.093
201512 0.199 99.792 0.263
201603 0.011 100.470 0.014
201606 0.005 101.688 0.006
201609 0.013 101.861 0.017
201612 -0.003 101.863 -0.004
201703 0.004 102.862 0.005
201706 0.017 103.349 0.022
201709 0.105 104.136 0.133
201712 0.039 104.011 0.049
201803 0.021 105.290 0.026
201806 0.019 106.317 0.024
201809 0.025 106.507 0.031
201812 0.027 105.998 0.034
201903 0.011 107.251 0.014
201906 0.010 108.070 0.012
201909 0.049 108.329 0.060
201912 0.025 108.420 0.030
202003 0.020 108.902 0.024
202006 0.019 108.767 0.023
202009 0.016 109.815 0.019
202012 0.023 109.897 0.028
202103 0.019 111.754 0.022
202106 0.020 114.631 0.023
202109 0.028 115.734 0.032
202112 0.021 117.630 0.024
202203 0.077 121.301 0.084
202206 0.091 125.017 0.096
202209 0.040 125.227 0.042
202212 0.038 125.222 0.040
202303 0.039 127.348 0.040
202306 0.026 128.729 0.027
202309 0.026 129.860 0.026
202312 0.012 129.419 0.012
202403 0.008 131.776 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (STU:I9DN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Arbutus Biopharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (STU:I9DN) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines